[A21-31] Avatrombopag (thrombocytopenia) - Benefit assessment according to §35a Social Code Book V
Last updated 01.07.2021
Project no.:
A21-31
Commission:
Commission awarded on 22.03.2021 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Haematology
Adult patients with severe thrombocytopenia and chronic liver disease who are scheduled to undergo an invasive procedure
- Moderate or high bleeding risk of the invasive procedure: proof of considerable added benefit.
- Low bleeding risk of the invasive procedure: added benefit not proven.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A21-32 | Avatrombopag (primary chronic immune thrombocytopenia) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A21-103 | Avatrombopag (thrombocytopenia) - Addendum to Commission A21-31 | Commission completed |
Federal Joint Committee (G-BA)
2021-09-16 A G-BA decision was published.